Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Meeting Calendar
  3. Past Meetings
  4. ESMO Congress 2024
  5. Satellite Symposia Webcasts

PeerVoice - Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate (ADC) Advances in Breast Cancer

ADCs for High-Risk Early HER2-Positive Breast Cancer: Are the Data Showing Potential?

Date

15 Sep 2024

Session

PeerVoice - Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate (ADC) Advances in Breast Cancer

Topics

Tumour Site

Breast Cancer

Presenters

Peter Schmid, Cristina Saura Manich, Aditya Bardia

Authors

P. Schmid1, C. Saura Manich2, A. Bardia3

Author affiliations

  • 1 Centre Of Experimental Cancer Medicine, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, EC1M 6BQ - London/GB
  • 2 /
  • 3 Medical Oncology Dept., UCLA - David Geffen School of Medicine, 90095 - Los Angeles/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Peter Schmid

Session: PeerVoice - Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate (ADC) Advances in Breast Cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.